Cargando…

Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors

Strategies to reduce the immunogenicity of pancreatic islets and to prevent the activation of proinflammatory events are essential for successful islet engraftment. Pretransplant islet culture presents an opportunity for preconditioning to improve outcomes of islet transplantation. We previously dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Naoya, Haga, Junichiro, Anazawa, Takayuki, Kenjo, Akira, Kimura, Takashi, Wada, Ikuo, Mori, Tsutomu, Marubashi, Shigeru, Gotoh, Mitsukazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680981/
https://www.ncbi.nlm.nih.gov/pubmed/28901184
http://dx.doi.org/10.1177/0963689717721233
_version_ 1783277869418414080
author Sato, Naoya
Haga, Junichiro
Anazawa, Takayuki
Kenjo, Akira
Kimura, Takashi
Wada, Ikuo
Mori, Tsutomu
Marubashi, Shigeru
Gotoh, Mitsukazu
author_facet Sato, Naoya
Haga, Junichiro
Anazawa, Takayuki
Kenjo, Akira
Kimura, Takashi
Wada, Ikuo
Mori, Tsutomu
Marubashi, Shigeru
Gotoh, Mitsukazu
author_sort Sato, Naoya
collection PubMed
description Strategies to reduce the immunogenicity of pancreatic islets and to prevent the activation of proinflammatory events are essential for successful islet engraftment. Pretransplant islet culture presents an opportunity for preconditioning to improve outcomes of islet transplantation. We previously demonstrated that ex vivo mitomycin C (MMC) pretreatment and subsequent culture significantly prolonged graft survival. Fully understanding the biological process of pretreatment could result in the development of a protocol to improve the survival of islet grafts. Microarrays were employed to conduct a comprehensive analysis of genes expressed in untreated or MMC-treated rat islets that were subsequently cultured for 3 d. A bioinformatics software was used to identify biological processes that were most affected by MMC pretreatment, and validation studies, including in vivo and in vitro assay, were performed. The gene expression analysis identified significant downregulation of annotated functions associated with cellular movement and revealed significant downregulation of multiple genes encoding proinflammatory mediators with chemotactic activity. Validation studies revealed significantly decreased levels of interleukin 6 (IL-6), monocyte chemoattractant protein 3 (MCP-3), and matrix metallopeptidase 2 (MMP2) in culture supernatants of MMC-treated islets compared with controls. Moreover, we showed the suppression of leukocyte chemotactic activity of MMC-treated islets in vitro. We also showed that MMC-treated islets secreted lower levels of chemoattractants that synergistically reduced the immunogenic potential of islets. Histological and immunohistochemical analyses of the implant site revealed that infiltration of monocytes, CD3-positive T cells, and B cells was decreased in MMC-treated islets. In conclusion, the ex vivo pretreatment of islets with MMC and subsequent culture can reduce the immunogenic potential and prolong the survival of islet grafts by inducing the suppression of multiple leukocyte chemotactic factors.
format Online
Article
Text
id pubmed-5680981
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-56809812017-11-21 Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors Sato, Naoya Haga, Junichiro Anazawa, Takayuki Kenjo, Akira Kimura, Takashi Wada, Ikuo Mori, Tsutomu Marubashi, Shigeru Gotoh, Mitsukazu Cell Transplant Original Articles Strategies to reduce the immunogenicity of pancreatic islets and to prevent the activation of proinflammatory events are essential for successful islet engraftment. Pretransplant islet culture presents an opportunity for preconditioning to improve outcomes of islet transplantation. We previously demonstrated that ex vivo mitomycin C (MMC) pretreatment and subsequent culture significantly prolonged graft survival. Fully understanding the biological process of pretreatment could result in the development of a protocol to improve the survival of islet grafts. Microarrays were employed to conduct a comprehensive analysis of genes expressed in untreated or MMC-treated rat islets that were subsequently cultured for 3 d. A bioinformatics software was used to identify biological processes that were most affected by MMC pretreatment, and validation studies, including in vivo and in vitro assay, were performed. The gene expression analysis identified significant downregulation of annotated functions associated with cellular movement and revealed significant downregulation of multiple genes encoding proinflammatory mediators with chemotactic activity. Validation studies revealed significantly decreased levels of interleukin 6 (IL-6), monocyte chemoattractant protein 3 (MCP-3), and matrix metallopeptidase 2 (MMP2) in culture supernatants of MMC-treated islets compared with controls. Moreover, we showed the suppression of leukocyte chemotactic activity of MMC-treated islets in vitro. We also showed that MMC-treated islets secreted lower levels of chemoattractants that synergistically reduced the immunogenic potential of islets. Histological and immunohistochemical analyses of the implant site revealed that infiltration of monocytes, CD3-positive T cells, and B cells was decreased in MMC-treated islets. In conclusion, the ex vivo pretreatment of islets with MMC and subsequent culture can reduce the immunogenic potential and prolong the survival of islet grafts by inducing the suppression of multiple leukocyte chemotactic factors. SAGE Publications 2017-09-13 2017-08 /pmc/articles/PMC5680981/ /pubmed/28901184 http://dx.doi.org/10.1177/0963689717721233 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Articles
Sato, Naoya
Haga, Junichiro
Anazawa, Takayuki
Kenjo, Akira
Kimura, Takashi
Wada, Ikuo
Mori, Tsutomu
Marubashi, Shigeru
Gotoh, Mitsukazu
Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors
title Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors
title_full Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors
title_fullStr Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors
title_full_unstemmed Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors
title_short Ex vivo Pretreatment of Islets with Mitomycin C: Reduction in Immunogenic Potential of Islets by Suppressing Secretion of Multiple Chemotactic Factors
title_sort ex vivo pretreatment of islets with mitomycin c: reduction in immunogenic potential of islets by suppressing secretion of multiple chemotactic factors
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680981/
https://www.ncbi.nlm.nih.gov/pubmed/28901184
http://dx.doi.org/10.1177/0963689717721233
work_keys_str_mv AT satonaoya exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT hagajunichiro exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT anazawatakayuki exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT kenjoakira exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT kimuratakashi exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT wadaikuo exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT moritsutomu exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT marubashishigeru exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors
AT gotohmitsukazu exvivopretreatmentofisletswithmitomycincreductioninimmunogenicpotentialofisletsbysuppressingsecretionofmultiplechemotacticfactors